Valion Bio reported favorable safety results from a government-funded preclinical study of Entolimod, its experimental drug candidate for acute radiation syndrome. The study, conducted by the Armed Forces Radiobiology Research Institute, found no evidence of treatment-related toxicity after a single dose in mice.
The completed safety work is intended to clear the way for a planned, fully funded study testing whether Entolimod can improve survival and gastrointestinal recovery after radiation exposure. That next study would assess therapeutic benefit, which the safety study did not test.
Key details
-
The safety study involved 20 male mice. Animals received either one subcutaneous dose of Entolimod at 0.72 mg/kg or a saline control and were observed for 14 days. The study was conducted by AFRRI under an agreement involving the National Institute of Allergy and Infectious Diseases’ Radiation and Nuclear Countermeasures Program and the Uniformed Services University.
-
Body weight and clinical observations showed no overall treatment-related concern. There was no statistically significant overall difference in mean body weight between Entolimod-treated and control animals. A temporary difference on day seven reflected weight gain in the saline group, rather than weight loss in the Entolimod group.
-
Blood counts and blood chemistry results were also reassuring. Measured blood-cell values remained within normal reference ranges, with no significant differences between groups. Tests of kidney, liver and metabolic function—including blood urea nitrogen, creatinine, glucose and liver enzymes—also showed no significant differences.
-
The next planned study shifts from safety to efficacy. AFRRI plans to use a specialized mouse model of gastrointestinal acute radiation syndrome to test Entolimod after radiation exposure, focusing on survival and recovery of gastrointestinal tissue. Valion described the study as fully funded but did not give a start date or report results from it.
Plain-English implications
The results add preliminary animal safety evidence for a single dose of Entolimod; they do not establish that the drug works against radiation injury or is safe in people. The planned study would address whether the treatment can improve outcomes after exposure, but those efficacy results are not yet available.